Articles producció científica> Medicina i Cirurgia

New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation

  • Identification data

    Identifier: imarina:6185073
    Handle: http://hdl.handle.net/20.500.11797/imarina6185073
  • Authors:

    Alegret, Josep M.
    Vinolas, Xavier
    Arias, Miguel A.
    Martinez-Rubio, Antoni
    Rebollo, Pablo
    Rafols, Carles
    Martinez-Sande, Jose L.
  • Others:

    Author, as appears in the article.: Alegret, Josep M.; Vinolas, Xavier; Arias, Miguel A.; Martinez-Rubio, Antoni; Rebollo, Pablo; Rafols, Carles; Martinez-Sande, Jose L.;
    Department: Medicina i Cirurgia
    URV's Author/s: Alegret Colomé, Josep Maria
    Keywords: Warfarin Vitamin k antagonists Self-management Ribaroxaban Prevention New oral anticoagulants Impact Health-related quality of life Events Elderly-patients Dabigatran Aspirin Ablation ribaroxaban. new oral anticoagulants health-related quality of life dabigatran
    Abstract: New oral anticoagulants (NOAC) have demonstrated their efficacy as an alternative to vitamin K antagonists (VKA) in the prophylaxis of cardioembolic events in patients with atrial fibrillation (AF). However, evidence on the benefits of NOAC in health-related quality of life (HRQoL) is lacking. We evaluated changes in HRQoL related to oral anticoagulation therapy employing a specific questionnaire in a cohort of 416 patients with AF undergoing electrical cardioversion. In terms of HRQoL, we observed a progressive adaptation to treatment with VKA; satisfaction with NOAC remained constant. Older age, higher left ventricular ejection fraction and NOAC were associated with better HRQoL.
    Thematic Areas: Odontología Medicine, general & internal Medicine (miscellaneous) Medicine (all) Medicina veterinaria Medicina ii Medicina i Materiais General medicine Farmacia Ensino Ciências biológicas ii Ciências biológicas i
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 14491907
    Author's mail: josepmaria.alegret@urv.cat
    Author identifier: 0000-0002-6117-5512
    Record's date: 2023-02-19
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.medsci.org/v11p0680.htm
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: International Journal Of Medical Sciences. 11 (7): 680-684
    APA: Alegret, Josep M.; Vinolas, Xavier; Arias, Miguel A.; Martinez-Rubio, Antoni; Rebollo, Pablo; Rafols, Carles; Martinez-Sande, Jose L.; (2014). New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. International Journal Of Medical Sciences, 11(7), 680-684. DOI: 10.7150/ijms.8916
    Article's DOI: 10.7150/ijms.8916
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2014
    Publication Type: Journal Publications
  • Keywords:

    Medicine (Miscellaneous),Medicine, General & Internal
    Warfarin
    Vitamin k antagonists
    Self-management
    Ribaroxaban
    Prevention
    New oral anticoagulants
    Impact
    Health-related quality of life
    Events
    Elderly-patients
    Dabigatran
    Aspirin
    Ablation
    ribaroxaban.
    new oral anticoagulants
    health-related quality of life
    dabigatran
    Odontología
    Medicine, general & internal
    Medicine (miscellaneous)
    Medicine (all)
    Medicina veterinaria
    Medicina ii
    Medicina i
    Materiais
    General medicine
    Farmacia
    Ensino
    Ciências biológicas ii
    Ciências biológicas i
  • Documents:

  • Cerca a google

    Search to google scholar